TY - JOUR
T1 - Chikungunya outbreaks in India
T2 - A prospective study comparing neutralization and sequelae during two outbreaks in 2010 and 2016
AU - Jain, Jaspreet
AU - Kaur, Navjot
AU - Haller, Sherry L.
AU - Kumar, Ankit
AU - Rossi, Shannan L.
AU - Narayanan, Vimal
AU - Kumar, Dilip
AU - Gaind, Rajni
AU - Weaver, Scott C.
AU - Auguste, Albert J.
AU - Sunil, Sujatha
N1 - Publisher Copyright:
Copyright © 2020 by The American Society of Tropical Medicine and Hygiene
PY - 2020
Y1 - 2020
N2 - Chikungunya fever (CHIKF) is a major public health concern and is caused by chikungunya virus (CHIKV). In 2005, the virus was reintroduced into India, resulting in massive outbreaks in several parts of the country. During 2010 and 2016 outbreaks, we recruited 588 patients from a tertiary care hospital in New Delhi, India, during the acute phase of CHIKF; collected their blood and clinical data; and determined their arthralgic status 12 weeks post-onset of fever. We evaluated IgM/IgG CHIKV-binding antibodies and their neutralizing capacity, sequenced complete genomes of 21 CHIKV strains, and correlated mutations with patient sequelae status. We also performed infections in murine models using representative strains from each outbreak to evaluate differences in pathogenesis. Our screening and analysis revealed that patients of the 2016 outbreak developed earlier IgM and neutralizing antibody responses that were negatively correlated with sequelae, compared with 2010 patients. Mutations that correlated with human disease progression were also correlated with enhanced murine virulence and pathogenesis. Overall, our study suggests that the development of early neutralizing antibodies and sequence variation in clinical isolates are predictors of human sequelae.
AB - Chikungunya fever (CHIKF) is a major public health concern and is caused by chikungunya virus (CHIKV). In 2005, the virus was reintroduced into India, resulting in massive outbreaks in several parts of the country. During 2010 and 2016 outbreaks, we recruited 588 patients from a tertiary care hospital in New Delhi, India, during the acute phase of CHIKF; collected their blood and clinical data; and determined their arthralgic status 12 weeks post-onset of fever. We evaluated IgM/IgG CHIKV-binding antibodies and their neutralizing capacity, sequenced complete genomes of 21 CHIKV strains, and correlated mutations with patient sequelae status. We also performed infections in murine models using representative strains from each outbreak to evaluate differences in pathogenesis. Our screening and analysis revealed that patients of the 2016 outbreak developed earlier IgM and neutralizing antibody responses that were negatively correlated with sequelae, compared with 2010 patients. Mutations that correlated with human disease progression were also correlated with enhanced murine virulence and pathogenesis. Overall, our study suggests that the development of early neutralizing antibodies and sequence variation in clinical isolates are predictors of human sequelae.
UR - http://www.scopus.com/inward/record.url?scp=85082801591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082801591&partnerID=8YFLogxK
U2 - 10.4269/ajtmh.19-0481
DO - 10.4269/ajtmh.19-0481
M3 - Review article
C2 - 32067624
AN - SCOPUS:85082801591
SN - 0002-9637
VL - 102
SP - 857
EP - 868
JO - American Journal of Tropical Medicine and Hygiene
JF - American Journal of Tropical Medicine and Hygiene
IS - 4
ER -